



Oligonucleotides-Based Therapeutics

Guest Editor:

Dr. Bernard Lebleu

Laboratory of Pathogen Host
Interactions, Biology-Health
Department, Montpellier
University, Montpellier, France

Deadline for manuscript
submissions:

closed (30 June 2021)

Message from the Guest Editor

Dear Colleagues,

Antisense oligonucleotides and small interfering RNAs are widely used tools to regulate sequence-specific gene expression. Although envisaged early on, clinical developments turned out more difficult to implement and the first successes have been documented only in the last few years. More recently, other nucleic acids-based strategies to regulate (or promote) gene expression have been proposed, including micro RNAs (or miRNA antagonists), splice switching oligonucleotides, immune-regulating oligonucleotides and messenger RNAs. Several FDA-approved drugs as well as promising clinical trials for the treatment of several diseases or for vaccine development have emerged. Reviews and original research articles dealing with fundamental research, the improvement of pharmacological properties (specificity of target recognition and delivery in particular), as well as pre-clinical development and clinical applications will be welcomed.

Dr. Bernard Lebleu

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)